Matt Erick
CCO, Biocon Limited
Notable Quotes
We have over 70% market access with the payers in the U.S. at the beginning of the start. With that comes the opportunity for us to continue to pull the product through in the U.S.
We are seeing very active growth and good growth in those other channels, like Semglee, trastuzumab, et cetera.